Uptake of 13-Valent Pneumococcal Conjugate Vaccine among US Adults Aged 19 to 64 Years with Immunocompromising Conditions
The CDC Advisory Committee on Immunization Practices (ACIP) recommended immunization with the recently licensed 13-valent pneumococcal conjugate vaccine (PCV13) for high-risk (immunocompromised) adults aged ≥19 years in 2012. This was in addition to the 23-valent pneumococcal polysaccharide vaccine...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Taylor & Francis Group
2020-01-01
|
| シリーズ: | Human Vaccines & Immunotherapeutics |
| 主題: | |
| オンライン･アクセス: | http://dx.doi.org/10.1080/21645515.2019.1632683 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|